关节炎患者血清肿瘤标志物CA199及CA153检测及临床价值被引量：2

下载PDF

导出

摘要目的探讨血清肿瘤标志物糖类抗原199(CA199)与糖类抗原153(CA153)检测应用于类风湿关节炎中的临床价值。方法选取2015年8月29日-2017年4月15日48例我院类风湿关节炎患者为观察组,另取同期我院其他疾病患者50例为对照组。两组均予以血清肿瘤标志物CA199、CA153检测。观察两组检测结果。结果观察组CA199、CA153检测阳性几率分别为27.08%、31.25%,相比对照组更高(P<0.05);C反应蛋白检测、红细胞沉降率检测阳性者与阴性者CA199水平对比性不强(P>0.05),CA153水平对比差异较大(P<0.05)。结论类风湿关节炎患者可见肿瘤标志物水平显著增高,临床可以此评估病情,制定科学治疗方案。

作者吴秀玲

机构地区河南省驻马店市平舆县人民医院检验科

出处《临床检验杂志（电子版）》 2017年第3期575-576,共2页 Clinical Laboratory Journal(Electronic Edition)

关键词肿瘤标志物类风湿关节炎 CA199 CA153

分类号 R446.6 [医药卫生—诊断学] R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献4

1欧阳霞,戴冽,朱浪静.骨代谢标志物的检测在类风湿关节炎中的临床意义[J].新医学,2012,43(2):71-74. 被引量：11
2曹贤,曹青凤,任水明.类风湿关节炎患者血清骨代谢标志物检测与分析[J].国际检验医学杂志,2017,38(12):1680-1682. 被引量：8
3王艳娇,李琳芸,彭长华,江涛,王昌富.类风湿关节炎患者血清炎性因子、ANCA水平与血管内皮损伤标志物的相关性分析[J].微循环学杂志,2012,22(1):49-51. 被引量：19
4张静思,陈鑫苹,陈斌.RF、抗-CCP、AKA及GPI联合检测在类风湿关节炎诊断中的价值[J].重庆医学,2015,44(13):1788-1789. 被引量：59

二级参考文献43

1YASUNORI K,MASAAKI T,TETSUYUKI N,et al.Reduction of urinary levels of pyridinoline and deoxypyr-idinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheu-matoid arthritis[J].Clin Rheumatol,2008,27(9):1093-1101.
2GARNERO P,THOMPSON E,WOODWORTH T,et al.Rapid and sustained improvement in bone and carti-lage turnover markers with the anti-interleukin-6recep-tor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to metho-trexate:results from a substudy of the multicenter doub-le-blind,placebo-controlled trial of to cilizumab in inad-equate responders to methotrexate alone[J].Arthritis Rheum,2010,62(1):33-43.
3HAYNES D,CROTTI T,WEEDON H,et al.Modula-tion of RANKL and osteoprotegerin expression in synovi-al tissue from patients with rheumatoid arthritis in re-sponse to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome[J].Arthritis Rheum,2008,59(7):911-920.
4WISL OWSKA M,JAKUBICZ D,STEPIEN'K,et al.Serum concentrations of formation(PINP)and resorp-tion(Ctx)bone turnover markers in rheumatoid arthritis[J].Rheumatol Int,2009,29(12):1403-1409.
5SYVERSEN S W,GOLL G L,VAN DER HEIJDE D,et al.Cartilage and bone biomarkers in rheumatoid ar-thritis:prediction of10-year radiographic progression[J].J Rheumatol,2009,36(2):266-272.
6SYVERSEN S W,HAAVARDSHOLM E A,BYESENP,et al.Biomarkers in early rheumatoid arthritis:longi-tudinal associations with inflammation and joint destruc-tion measured by magnetic resonance imaging and con-ventional radiographs[J].Ann Rheum Dis,2010,69(5):845-850.
7VAN TUYL L H,VOSKUYL A E,BOERS M,et al.Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progres-sion over11years in rheumatoid arthritis[J].Ann Rheum Dis,2010,69(9):1623-1628.
8TORIKAI E,KAGEYAMA Y,TAKAHASHI M,et al.The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis[J].Mod Rheuma-tol,2006,16(6):350-354.
9HASHIMOTO J,GARNERO P,VAN DER HEIJDE D,et al.A combination of biochemical markers of cartilage and bone turnover,radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs[J].Mod Rheumatol,2009,19(3):273-282.
10ENGVALL I L,SVENSSON B,TENGSTRAND B,et al.Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis:experiences from a two-year randomized study[J].Arthritis Res Ther,2008,10(6):R128.